Document Detail

Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia.
MedLine Citation:
PMID:  11595398     Owner:  NLM     Status:  MEDLINE    
We have previously reported that average striatal dopamine transporter (DAT) binding in vivo is unaltered in neuroleptic-naive first-episode schizophrenic patients [Laakso et al., Am. J. Psychiatry 157 (2000) 269]. However, as it has been suggested that some of the brain changes in schizophrenia may vary depending on the illness phase, we studied DAT density in eight stable, medicated chronic schizophrenic patients and eight matched controls using positron emission tomography and [18F]CFT, a marker of dopamine nerve terminals. [18F]CFT binding potentials were significantly lower in chronic schizophrenic patients than in controls, both in the caudate and the putamen (-9 to -16%). Together with the finding of unchanged average striatal DAT levels in first-episode patients and relative insensitivity of striatal [18F]CFT binding to endogenous dopamine and neuroleptic drugs, the result is in line with a relative loss of striatal dopaminergic nerve terminals and/or decreased expression of DAT in a subset of chronic schizophrenic patients.
A Laakso; J Bergman; M Haaparanta; H Vilkman; O Solin; E Syvälahti; J Hietala
Related Documents :
4063588 - Third ventricle size and dementia in schizophrenia.
3058828 - Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone re...
3626198 - Chilaiditi's syndrome in schizophrenic patients.
2906088 - Topographic subtypes of tardive dyskinesia in schizophrenic patients aged less than 60 ...
17998458 - Left ventricular untwisting rate by speckle tracking echocardiography.
14626848 - Diagnostic abilities of three cad methods for assessing microcalcifications in mammogra...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Schizophrenia research     Volume:  52     ISSN:  0920-9964     ISO Abbreviation:  Schizophr. Res.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-11     Completed Date:  2001-12-18     Revised Date:  2010-09-02    
Medline Journal Info:
Nlm Unique ID:  8804207     Medline TA:  Schizophr Res     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  115-20     Citation Subset:  IM    
Department of Pharmacology and Clinical Pharmacology, University of Turku, 20520, Turku, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Brain Mapping
Chronic Disease
Cocaine / analogs & derivatives*,  pharmacokinetics
Corpus Striatum / radionuclide imaging*
Dominance, Cerebral / physiology
Dopamine Plasma Membrane Transport Proteins
Dopamine Uptake Inhibitors / pharmacokinetics
Membrane Glycoproteins*
Membrane Transport Proteins / metabolism*
Nerve Tissue Proteins*
Psychiatric Status Rating Scales
Radioligand Assay
Schizophrenia / physiopathology,  radionuclide imaging*
Tomography, Emission-Computed*
Reg. No./Substance:
0/Dopamine Plasma Membrane Transport Proteins; 0/Dopamine Uptake Inhibitors; 0/Membrane Glycoproteins; 0/Membrane Transport Proteins; 0/Nerve Tissue Proteins; 0/SLC6A3 protein, human; 50-36-2/Cocaine; 50370-56-4/(1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transpo...
Next Document:  Phospholipid patterns of erythrocytes in schizophrenia: relationships to symptomatology.